DOCSLIB.ORG

Beyond Monoamines Towards the Development of Novel Antidepressants Oltre Le Monoamine Al Fine Di Sviluppare Nuovi Farmaci Antidepressivi

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Beyond Monoamines Towards the Development of Novel Antidepressants Oltre Le Monoamine Al Fine Di Sviluppare Nuovi Farmaci Antidepressivi Original article • Articolo originale Beyond monoamines towards the development of novel antidepressants Oltre le monoamine al fine di sviluppare nuovi farmaci antidepressivi M. Fornaro1,2 1 Department of “Scienze della Formazione”, University of Catania, Italy; 2 Department of Psychiatry, Veteran Affairs (VA) Hospital, University of California (UCSD), La Hoya, San Diego, CA, USA Summary ated giving priority to RCTs and meta-analyses. At present, the pharmacological management of depression appears is Objective characterized by a wide variety of different augmentation or Herein, a concise review is presented on the current and most switching approaches (Fig. 1). Nonetheless, response rates promising antidepressant pharmacological agents for manage- remain substantially unsatisfactory, thus prompting for the ment of depression. development of novel agents with different mechanisms of action. Materials and methods A PubMed search (1966 - February 2012) was performed using Conclusions the following keywords or their combination: “depression”; Shifting the interest for novel antidepressant drugs beyond the “major depressive disorder”: “antidepressants”; “novel antide- monoaminergic modulation represents (Tables I-III) an intriguing pressant targets”; “monoamine”; “novel antidepressants”. Ad- opportunity to enhance response rates of depression, although ditional literature sources, including most authoritative and up- other issues, including revision of current nosological bounda- dated edited books or pamphlets were examined accordingly. ries, should also be considered. Results Key words All relevant literature sources written in English were evalu- Monoamines • Antidepressant drugs • Novel targets Introduction high priority of pharmaceutical companies 7. The situation changed in 1988, when the introduction of fluoxetine, a Depression is one of the most prevalent psychiatric selective serotonin reuptake inhibitor (SSRI) approved for disorders, and has unfavourable prognosis with con- the treatment of major depressive disorder (MDD) 8, alter- siderable suicide risk 1. Its lifetime prevalence rate in natively generically labelled as “depression”, marked the the United States is estimated to be 16.6%, affecting beginning of a “golden era” of the pharmacological treat- over 30 million people, with more than 80% of these ment of the disorder 9. In fact, although not as effective as individuals experiencing recurrent episodes 2 3. None- theless, despite the clinical and social relevance of the the previously introduced tricyclic antidepressants (TCAs) 10 11 phenomenon, depression still faces considerableEPUB unsat- and monoamine oxidase inhibitors (MAO-Is) , the SS- isfactory response rates, thus soliciting the exploration RIs and the latter introduced classes of antidepressants, of novel therapeutic targets to develop more effective still ensured substantial remission rates compared to pla- interventions. cebo while providing a better tolerability profile (although Concerning the pharmacological treatment of depres- not completely devoid of side-effects), thus contributing sion, currently the cornerstone of clinical management, to the widespread pharmacological management of de- numerous agents from different classes have been pro- pression 12 13. Nonetheless, the need for higher response posed since the 1950s, when the mood-enhancing prop- rates for the antidepressant treatment solicited the intro- erties of two anti-tuberculosis agents, isoniazid and ip- duction of novel compounds as well the implementation roniazid 4 5 and imipramine, also a tricyclic compound 6 of enhanced augmentation or switching strategies for cur- were serendipitously observed. Unfortunately, at that time rently available drugs. the number of people diagnosed with “depression” who In this review, the prominent pharmacological opportu- would benefit from these “new” agents was very low, nities for the treatment of depression are briefly outlined, so that the development of antidepressants was not the focusing on novel non-monoaminergic compounds. Correspondence Michele Fornaro, via Teatro Greco 84, 95100 Catania, Italia • Tel. +39 347 4140003 • Fax +39 010 3537681 • E-mail: [email protected] Journal of Psychopathology 2012; EPUB April 19, 2012 1 M. Fornaro Materials and methods As a major implication, this possibility has suggested that other antidepressant targets should be explored. Considered sources included all PubMed results written in English (updated to February 2012) systematically re- trieved using the following keywords or their combina- The need for novel antidepressant drugs: tion: “depression”; “major depressive disorder”: “antide- the increasingly crowded antidepressant pressants”; “novel antidepressant targets”; “monoamine”; scenario “novel antidepressants”. Additional literature sources, in- Both pharmacological and clinical considerations con- cluding most authoritative and updated edited books or cerning the efficacy, safety, tolerability and costs influ- pamphlets were evaluated accordingly. ence compliance and outcome of the depressed patient, soliciting novel antidepressant interventions. Results The need for an anticipated onset of action Two hundred and eighty nine randomized clinical tri- als (RCTs) or meta-analyses were assessed, while non- A lag phase of at least 3-4 weeks prior to the onset of an controlled studies were used only when controlled data antidepressant effect is commonly seen with current anti- 27 unavailable. Finally, studies performed in humans were depressant drugs , in contrast with an almost immediate prioritized, while pre-clinical or animal investigations increase in monoamine extracellular levels evident just have been cited only in the absence of corresponding few hours initiation of therapy. evidence in human samples. At least two types of 5-HT auto-receptors are present on the serotonergic neuron. Activation of 5-HT1A recep- tors, present in the somatodendritic area, reduces neu- The monoamine hypothesis of depression ronal firing, resulting in less serotonin release from the and beyond axon terminal. On the other hand, activation of 5-HT1B Since its first conceptualization, 14-16 the “monoamine receptors causes direct inhibition of serotonin release. hypothesis of depression” largely influenced the devel- 5-HT1A is also related to control of serotonergic release opment of novel antidepressant drugs and prescribing through a large feedback loop from terminal to the cell 28 attitudes of clinicians toward MDD 17. This hypothesis body region . It is likely that these auto-restraining proc- essentially focuses on increasing the levels and syn- esses counteract the initial effect of SSRIs as well as other aptic effects of three monoamines, namely dopamine classes of antidepressant drugs that primarily act by sero- (DA), norepinephrine (NE) and the indole amine 5-hy- tonergic modulation, and chronic administration of these droxytryptamine (5-HT) or serotonin, to induce an anti- agents is reported to desensitize both presynaptic and 29 depressant response 18-20. Within the past decades, this postsynaptic 5-HT1A receptors . hypothesis has undergone extensive revision, leading to Similarly, complex pre- and post-synaptic modulations the observation that such synaptic modificationsEPUB would concern norepinephrinergic modulation. The alpha-2 be due to blockade of monoamine transporters, includ- norepinephrinergic auto-receptors, located both on ax- ing the dopamine transporter (DAT), the norepinephrine on terminals and cell bodies, establish an effective self- transporter (NET) and the serotonin transporter (SERT) 19. regulation system similar to that in serotonergic neurons, However, monoamine levels can increase rapidly fol- which is also believed to become supersensitive during 30 lowing blockade of these transporters, much earlier than depression , while the beta-adrenoceptors are located onset of clinical action, if ever 21 22. The “neurotransmit- post-synaptically. Up-regulation of these receptors has ter receptor sensitivity hypothesis” of depression can been observed in the course of depression, whereas explain this lag phase 23, and is also in agreement with down-regulation of these latter has been related to anti- 31 the neurotransmitter receptor hypothesis focusing on the depressant activity . Nonetheless, despite the discovery abnormal up-regulation of receptors during the course of of the mechanisms held to be responsible, overcoming depression 24. Nonetheless, it is likely that modifications the lag phase of antidepressant drugs remains an unad- in receptor number and/or sensitivity following antide- dressed need 32. pressant treatment require alterations in gene expression, transcription, translation and production of various neu- The need for more effective antidepressants: rotrophic factors as the brain derived neurotrophic factor beyond the SSRIs (BDNF) 25 26. Thus, in addition to modulating monoam- The SSRIs are still the most commonly prescribed antide- ine and receptor levels, the final common pathway of all pressant drugs 13. Nonetheless, their efficacy has highly antidepressants should involve the regulation of various debated, especially for most severe cases of depression 33, trophic factors, rather than just the monoamine balance. which have favoured the use of serotonin norepinephrine 2 Beyond monoamines towards the development of novel antidepressants FIGURE 1. Switching and augmentation of strategies are part of routine psychopharmacological practice of the treatment of depression,
Load more

Recommended publications
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • National Horizon Scanning Centre Amibegron
    National Horizon Scanning Centre Amibegron (SR–58611) for depression April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes. The National Horizon Scanning Centre Research Programme is part of the National Institute for Health Research April 2008 National Horizon Scanning Centre News on emerging technologies in healthcare Amibegron (SR–58611) for depression Target group • Major depressive disorder (MDD). Technology description Amibegron is a selective beta 3-adrenoceptor, which stimulates neuronal activity in a specific area of the prefrontal cortex. Amibegron is an oral formulation administered at 175mg or 350mg twice daily. Innovation and/or advantages Amibegron is the first in a new class of antidepressant agents. It is anticipated that it will have less toxicity than current treatments. Developer Sanofi-Aventis. Availability, launch or marketing dates, and licensing plans: In phase III clinical trials. NHS or Government priority area: This topics relates to the National service framework for mental health: modern standards and service models. 19991. Relevant guidance • NICE technology appraisal. Depression and anxiety - Computerised cognitive behaviour therapy for depression and anxiety. 20062. • NICE clinical guideline in development. Depression - primary and secondary care: The treatment and management of depression in primary and secondary care. Expected June 20093. • NICE clinical guideline in development. Depression - chronic health problems: The treatment of depression in people with chronic physical health problems. Expected June 20094. • NICE clinical guideline.
    [Show full text]
  • Objectives Results Material-Methods
    v ANXIOLYTIC-LIKE EFFECT OF BETA RECEPTOR AGONIST AMIBEGRON (SR 58611A) WHICH MAY BE RELATED TO INTERACTION OF SEROTONIN RECEPTOR SUBTYPES 1 1 2 2 2 2 2 Pelin Tanyeri , Mehmet Emin Büyükokuroğlu , Oguz Mutlu , Güner Ulak , Füruzan Yıldız Akar , İpek Komşuoğlu Çelikyurt , Bekir Faruk Erden 1 Sakarya University, Faculty of Medicine, Department of Pharmacology, 54100-Sakarya/Turkey, 2 Kocaeli University, Faculty of Medicine, Department of Pharmacology, 41380-Kocaeli/Turkey OBJECTIVES THE AIM OF THE STUDY MATERIAL-METHODS Anxiety disorders are the most common and prevalent behavioral disorders with high comor- This study is aimed to investigate the effects of the first selective beta3 adrenergic agent ami- We used the serotonin 5HT1A receptor antagonist WAY-100635, serotonin 5HT2A-2C re- bidity rates. The decrease of the serotonergic activity and dysregulation of catecholaminer- begron on anxiety and also the involvement of different serotonin receptor subtypes in this ceptor antagonist ketanserin and serotonin 5HT3 receptor antagonist ondansetron in the ele- gic system may play a role in the pathogenesis of anxiety. effect. vated plus maze test. RESULTS CONCLUSION DISCLOSURE PANELS Amibegron (5 and 10 mg/kg) dose dependently prolonged the time spent in open arms and the number of entries to the open arms in mice EPM test. WAY, ketanserin and ondanset- In conclusion, amibegron exerted significant anxiolytic-like ef- Nothing to disclose ron had no effect on the time spent in open arms and the number of entries to the open arms in mice and also they all significantly reversed amibegron (10 mg/kg)-induced increase in fects in the mice EPM test which was as effective as diazepam.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • GPCR/G Protein
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com GPCR/G Protein G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na+/H+ exchanger in the plasma membrane, and the lowering of intracellular Ca2+ levels. Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system. A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs. References: [1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33.
    [Show full text]
  • Using Tests and Models to Assess Antidepressant-Like Activity in Rodents Ewa Kedzierska1*, Izabela Wach2
    DOI: 10.1515/cipms-2016-0013 Curr. Issues Pharm. Med. Sci., Vol. 29, No. 2, Pages 61-65 Current Issues in Pharmacy and Medical Sciences Formerly ANNALES UNIVERSITATIS MARIAE CURIE-SKLODOWSKA, SECTIO DDD, PHARMACIA journal homepage: http://www.curipms.umlub.pl/ Using tests and models to assess antidepressant-like activity in rodents Ewa Kedzierska1*, Izabela Wach2 1 Chair and Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, Chodzki 4A, 20-093 Lublin, Poland 2 Student Research Group at the Chair and Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, Chodzki 4A, 20-093 Lublin, Poland ARTICLE INFO ABSTRACT Received 08 February 2016 In today's world, depression is one of the more prevalent forms of mental illness. According Accepted 10 March 2016 to WHO, about 10%-30% of all women and 7%-15% of all men are afflicted by depression Keywords: at least once in their life-times. Today, depression is assessed to be affecting 350 million depression, people. Regarding this issue, an important challenge for current psychopharmacology animal models, is to develop new, more effective pharmacotherapy and to understand the mechanism atidepressants. of action of known antidepressants. Furthermore, there is the necessity to improve the effectiveness of anti-depression treatment by way of bringing about an understanding of the neurobiology of this illness. In achieving these objectives, animal models of depression can be useful. Yet, presently, all available animal models of depression rely on two principles: the actions of known antidepressants or the responses to stress. In this paper, we present an overview of the most widely used animal tests and models that are employed in assessing antidepressant-like activity in rodents.
    [Show full text]
  • Datasheet Inhibitors / Agonists / Screening Libraries a DRUG SCREENING EXPERT
    Datasheet Inhibitors / Agonists / Screening Libraries A DRUG SCREENING EXPERT Product Name : Amibegron hydrochloride Catalog Number : T10302 CAS Number : 121524-09-2 Molecular Formula : C22H27Cl2NO4 Molecular Weight : 440.36 Description: Amibegron hydrochloride is a selective β3-adrenoceptor agonist (EC50: 3.5 nM for β-adrenoceptor in rat colon). It has anxiolytic and antidepressant activity. Storage: 2 years -80°C in solvent; 3 years -20°C powder; Receptor (IC50) β-adrenoceptor 499 nM In vitro Activity Amibegron hydrochloride (SR 58611A) is a selective β-adrenoceptor agonist (EC50: 499 nM in rat uterus) [1]. Amibegron hydrochloride shows little effect on β1- and β2-adrenoceptors, 5-HT uptake, noradrenaline (NA) uptake, and dopamine (DA) uptake from rat brain tissue (IC50s: 4.6 and 1.2, 0.58, 2.5 and 3.2 μM). It exhibits no effect on 5-HT1A, 5-HT2, MAO-A, and MAO-B (IC50 > 10 μM) [2]. In vivo Activity Amibegron hydrochloride (0.1 to 0.3 mg/kg, i.p.) potentiates the toxicity produced by yohimbine in mice. Amibegron hydrochloride (0.6 and 2 mg/kg, i.p.) is also active in the learned helplessness model of antidepressant-like activity in rats [2]. Amibegron hydrochloride (3 and 10 mg/kg, p.o.) increases the synthesis of 5-HT and tryptophan (Trp) levels in several rodent brain areas such as cortex, hippocampus, hypothalamus. In addition, Amibegron hydrochloride (10 mg/kg, p.o.) promotes the release of 5-HT in the rat prefrontal cortex. Systemic (3 mg/kg, i.v.) or chronic administration of SR58611A (10 mg/kg, p.o.) does not affect the activity of serotonergic neurons in the rat dorsal raphe nucleus [3].
    [Show full text]
  • Impact of Depressogenic- and Antidepressant-Like
    Impact of depressogenic- and antidepressant-like challenges on monoamine system activities: in vivo electrophysiological characterization studies Chris A. Oosterhof Department of Cellular & Molecular Medicine University of Ottawa Thesis submitted in partial fulfillment of the requirements for the Doctor of Philosophy Degree in Neuroscience © Chris A. Oosterhof, Ottawa, Canada, 2016 Table of contents Table of contents ............................................................................................................. ii Acknowledgements ........................................................................................................ iv Statement of contributions .............................................................................................. v List of figures ................................................................................................................. vi List of tables .................................................................................................................. vii Glossary ........................................................................................................................ viii Abstract .......................................................................................................................... xi 1) Major depressive disorder ............................................................................................... 1 2) Monoamine systems.......................................................................................................
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Фармакология Pharmacology
    МИНИСТЕРСТВО ЗДРАВООХРАНЕНИЯ РЕСПУБЛИКИ БЕЛАРУСЬ БЕЛОРУССКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ КАФЕДРА ФАРМАКОЛОГИИ ФАРМАКОЛОГИЯ PHARMACOLOGY Практикум для специальности «Лечебное дело» 5-е издание, переработанное Минск БГМУ 2020 2 УДК 615(076.5)(075.8)-054.6 ББК 52.81я73 Ф24 Рекомендовано Научно-методическим советом университета в качестве практикума 29.05.2020 г., протокол № 9 А в т о р ы: проф. Н. А. Бизунок, проф. Б. В. Дубовик, доц. Б. А. Волынец, доц. А. В. Волчек Р е ц е н з е н т ы: д-р мед. наук, проф. А. В. Хапалюк; д-р. мед. наук, проф. А. И. Волотовский Фармакология = Pharmacology : практикум для специальности «Лечебное дело» / Ф24 Н. А. Бизунок [и др.]. – 5-е изд., перераб. – Минск : БГМУ, 2020. – 156 с. ISBN 978-985-21-0643-6. Содержит методические рекомендации для подготовки к лабораторным занятиям по фармакологии и задания для самостоятельной работы студентов, обучающихся по специальности 1-79 01 01 «Лечебное дело». Первое издание вышло в 2016 году. Предназначен для студентов 3-го курса медицинского факультета иностранных учащихся, изучающих фармакологию на английском языке. УДК 615(076.5)(075.8)-054.6 ББК 52.81я73 ISBN 978-985-21-0643-6 © УО «Белорусский государственный медицинский университет», 2020 3 CONTENTS INTRODUCTION ............................................................................................................................................................. 4 GENERAL PRESCRIPTION ...........................................................................................................................................
    [Show full text]
  • 5-HT2A Receptors in the Central Nervous System the Receptors
    The Receptors Bruno P. Guiard Giuseppe Di Giovanni Editors 5-HT2A Receptors in the Central Nervous System The Receptors Volume 32 Series Editor Giuseppe Di Giovanni Department of Physiology & Biochemistry Faculty of Medicine and Surgery University of Malta Msida, Malta The Receptors book Series, founded in the 1980’s, is a broad-based and well- respected series on all aspects of receptor neurophysiology. The series presents published volumes that comprehensively review neural receptors for a specific hormone or neurotransmitter by invited leading specialists. Particular attention is paid to in-depth studies of receptors’ role in health and neuropathological processes. Recent volumes in the series cover chemical, physical, modeling, biological, pharmacological, anatomical aspects and drug discovery regarding different receptors. All books in this series have, with a rigorous editing, a strong reference value and provide essential up-to-date resources for neuroscience researchers, lecturers, students and pharmaceutical research. More information about this series at http://www.springer.com/series/7668 Bruno P. Guiard • Giuseppe Di Giovanni Editors 5-HT2A Receptors in the Central Nervous System Editors Bruno P. Guiard Giuseppe Di Giovanni Faculté de Pharmacie Department of Physiology Université Paris Sud and Biochemistry Université Paris-Saclay University of Malta Chatenay-Malabry, France Msida MSD, Malta Centre de Recherches sur la Cognition Animale (CRCA) Centre de Biologie Intégrative (CBI) Université de Toulouse; CNRS, UPS Toulouse, France The Receptors ISBN 978-3-319-70472-2 ISBN 978-3-319-70474-6 (eBook) https://doi.org/10.1007/978-3-319-70474-6 Library of Congress Control Number: 2017964095 © Springer International Publishing AG 2018 This work is subject to copyright.
    [Show full text]
  • Mechanisms of Antidepressant Resistance
    REVIEW ARTICLE published: 22 November 2013 doi: 10.3389/fphar.2013.00146 Mechanisms of antidepressant resistance Wissam El-Hage 1,2, Samuel Leman 1, Vincent Camus 1,2 and Catherine Belzung 1* 1 INSERM 930, Faculté de Sciences et Techniques, Université François Rabelais, Tours, France 2 Centre Hospitalier Régional Universitaire de Tours, Centre Expert Dépression Résistante, Fondation FondaMental, Tours, France Edited by: Depression is one of the most frequent and severe mental disorder. Since the discovery Thibault Renoir, Florey Institute of of antidepressant (AD) properties of the imipramine and then after of other tricyclic Neuroscience and Mental Health, compounds, several classes of psychotropic drugs have shown be effective in treating Australia major depressive disorder (MDD). However, there is a wide range of variability in response Reviewed by: Jean-Philippe Guilloux, Université to ADs that might lead to non response or partial response or in increased rate of relapse Paris Sud, France or recurrence. The mechanisms of response to AD therapy are poorly understood, and few Andre Carvalho, Federal University biomarkers are available than can predict response to pharmacotherapy. Here, we will first of Ceara, Brazil review markers that can be used to predict response to pharmacotherapy, such as markers *Correspondence: of drug metabolism or blood-brain barrier (BBB) function, the activity of specific brain areas Catherine Belzung, INSERM 930, Faculté de Sciences et Techniques, or neurotransmitter systems, hormonal dysregulations or plasticity, and related molecular Université François Rabelais, Parc targets. We will describe both clinical and preclinical studies and describe factors that Grandmont, F-37200 Tours, France might affect the expression of these markers, including environmental or genetic factors e-mail: catherine.belzung@ and comorbidities.
    [Show full text]